

Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA

November 12, 2020

-- Ten Additional Technology Leaders Join Founding Members to Together Advance Industry Roadmap, Set Stage for Widespread Adoption of New Long-term Storage Option --

-- Announcement at Flash Memory Summit --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 12, 2020-- <u>Twist Bioscience Corporation</u> (NASDAQ: TWST), <u>Illumina. Inc</u>. (NASDAQ: ILMN) and <u>Western Digital</u> (NASDAQ: WDC) today announced the formation of an alliance with Microsoft to advance the field of DNA data storage. These founding companies, alongside member organizations, will work together to create a comprehensive industry roadmap that will help the industry achieve interoperability between solutions and help establish the foundations for a cost-effective commercial archival storage ecosystem for the explosive growth of digital data.

"DNA is an incredible molecule that, by its very nature, provides ultra-high-density storage for thousands of years," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "By joining with other technology leaders to develop a common framework for commercial implementation, we drive a shared vision to build this new market solution for digital storage."

DNA data storage has the potential to deliver a true low-cost archival data storage solution. While current storage technologies have limited longevity and require data migration for long-term data storage, DNA provides a stable format storage medium that is durable for thousands of years when properly stored. In addition, DNA enables cost effective and rapid duplication. Importantly, it is incredibly dense, with 10 full length digital movies fitting into a volume the size of a single grain of salt. Digital data stored in DNA can be stored in a variety of containers including capsules, pellets or encased in glass beads.

"At Microsoft Research, we proactively address the future challenges of technology, with sustainability in mind," commented Karin Strauss, Ph.D., senior principal research manager at Microsoft. "In collaboration with University of Washington, we have demonstrated a fully automated end-to-end system capable of storing and retrieving data from DNA, and we have separately stored 1GB of data in DNA synthesized by Twist and recovered data from it. We're encouraged by the potential for more sustainable data storage with DNA and look forward to collaborating with others in the industry to explore early commercialization of this technology."

By 2024, 30% of digital businesses will mandate DNA storage trials, addressing the exponential growth of data poised to overwhelm existing storage technology.¹

"There is an unmet need for a new long-term archival storage medium that keeps up with the rate of digital data growth," said Steffen Hellmold, vice president corporate strategic initiatives, Western Digital. "We estimate that almost half of the data storage solutions shipped in 2030 will be used to archive data as the overall temperature of data is cooling down. We are committed to providing a full portfolio of storage solutions addressing the demand for hot, warm and cold storage."

"A key component of a DNA data storage system is its ability to read back the digital information when needed," stated Alex Aravanis, M.D., Ph.D., chief technology officer at Illumina. "We believe Illumina's innovative sequencing technology will be critical in enabling this market at commercial scale and look forward to collaborating with other leaders in their respective fields to make this a viable, long-term solution for archival storage."

Twist Bioscience, Illumina, Western Digital and Microsoft are joining the Alliance as founding members. In addition to developing an industry roadmap, the DNA Data Storage Alliance plans to develop use cases in various markets and industries as well as promote and educate the larger storage community to promote adoption of this future solution. The following organizations have joined the alliance as members:

- <u>Ansa Biotechnologies</u>
- CATALOG
- The Claude Nobs Foundation (Montreux Jazz Digital Project)
- DNA Script
- EPFL (École Polytechnique Fédérale de Lausanne) Cultural Heritage & Innovation Center (Montreux Jazz Digital Project)
- ETH Zurich The Swiss Federal Institute of Technology in Zurich, Switzerland
- imec
- Iridia
- Molecular Assemblies
- Molecular Information Systems Lab at the University of Washington

The Alliance welcomes additional participation from organizations within DNA and data storage industries that would like to contribute to this emerging ecosystem.

How to Store Digital Data in DNA

To store data in DNA, first, a data file is converted from its digital sequence of 0's and 1's into a DNA sequence of A's, C's, T's and G's. The DNA data file is then synthesized ("written") in short segments of DNA (200 to 300 bases long) and stored. In addition to storing part of the data file, each short segment contains an index to indicate its place within the overall data file. To retrieve the data, the segments are sequenced ("read") and then decoded back into the original file. One feature of the indexing system is it allows part of the file to be biologically recovered ("random access") before sequencing, so only data of interest is sequenced. In addition, all data is recovered error-free because error-correcting algorithms are used during the encode/decode process. For a short video of the process watch: https://www.youtube.com/watch?v=LTnJWxCO3M4.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit <u>www.illumina.com</u> and connect with us on <u>Twitter</u>, <u>Facebook</u>, <u>LinkedIn</u>, <u>Instagram</u>, and <u>YouTube</u>.

About Western Digital

Western Digital creates environments for data to thrive. As a leader in data infrastructure, the company is driving the innovation needed to help customers capture, preserve, access and transform an ever-increasing diversity of data. Everywhere data lives, from advanced data centers to mobile sensors to personal devices, our industry-leading solutions deliver the possibilities of data. Our data-centric solutions are comprised of the Western Digital®, G-Technology™, SanDisk®, and WD® brands.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation, the ability of the Alliance to advance DNA data storage, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; scientific unknowns and new information relating to the SARS-CoV-2 virus; the duration, extent and impact of the COVID-19 pandemic; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Western Digital Forward-Looking Statements Disclaimer

This news release contains certain forward-looking statements, including expectations regarding the future applications, advances and success of DNA data storage and Western Digital's expectations regarding its portfolio of storage solutions. There are a number of risks and uncertainties that may cause these forward-looking statements to be inaccurate including, among others: future responses to and effects of the COVID-19 pandemic; volatility in global economic conditions; impact of business and market conditions; impact of competitive products and pricing; our development and introduction of products based on new technologies and expansion into new data storage markets; risks associated with cost saving initiatives, restructurings, acquisitions, divestitures, mergers, joint ventures and our strategic relationships; difficulties or delays in manufacturing or other supply chain disruptions; hiring and retention of key employees; our high level of debt and other financial obligations; changes to our relationships with key customers; disruptions in operations from cyberattacks or other system security risks; actions by competitors; risks associated with compliance with changing legal and regulatory requirements and the outcome of legal proceedings; and other risks and uncertainties listed in Western Digital's filings with the Securities and Exchange Commission (the "SEC"), including Western Digital's Form 10-K filed with the SEC on August 28, 2020, to which your attention is directed. You should not place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Western Digital undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

¹Gartner Press Release, "Gartner Unveils Top Predictions for IT Organizations and Users in 2021 and Beyond", October 21, 2020 <u>https://www.gartner.com/en/newsroom/press-releases/2020-10-21-gartner-unveils-top-predictions-for-it-organizations-and-users-in-2021-and-beyond</u>

Contacts for Twist Bioscience:

Investor Contact: Argot Partners Maeve Conneighton 212-600-1902 maeve@argotpartners.com

Media Contact: Angela Bitting 925- 202-6211 media@twistbioscience.com

Contacts for Western Digital Media Contact: Lisa Neitzel 1-408-717-7607 lisa.neitzel@wdc.com

Investor Contact: T. Peter Andrew +1-949-672-9655 peter.andrew@wdc.com investor@wdc.com

Contact for Illumina: Dr. Karen Birmingham 1-646-355-2111 kbirmingham@illumina.com

Source: Twist Bioscience Corporation